Filter posts

Mayo v. Prometheus: BIO Statement on Supreme Court Decision

By Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization We are surprised and …

Patent "Ever-Greening": Novartis Confronts Patent Myth in India

India’s ‘increased efficacy’ patentability requirement for medicines prevents an improved form of a known drug …

BIO IP Counsels Conference Agenda Topics

Join us in Austin for BIO’s Intellectual Property Counsels Committee Conference on April 16-18.  Agenda …

Patents for Humanity

By David Kappos, Director of the United States Patent and Trademark Office (USPTO) Originally Published on …

PTO Genetic Testing Study: What's Patents Got to Do with It

The USPTO held a hearing on February 16 to collect testimony from interested parties to …

Biotech IP Challenges Around the World: BIO’s Special 301 Submission

BIO recently submitted its Special 301 Submission highlighting intellectual property (IP) challenges around the world.  …

AUTM Website Helps Commercialize University Technologies

By Robin L. Rasor, CLP, RTTP, AUTM President As president of the Association of University …

Patent Awards for Humanitarian Ventures

The USPTO recently announced the Patents for Humanity Challenge which awards patent owners and licensees …

Is the Polio Vaccine an Anti-Patent Success Story?

By Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization Question from a Reader: …

The Real Reason Why Salk Refused to Patent the Polio Vaccine

Editor’s Note: Despite the progress in polio and other diseases made possible by vaccines, today …